News & Updates

A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.

Extending the infusion duration of paclitaxel in breast cancer patients with low skeletal muscle area is expected to reduce peripheral neuropathy while maintaining systemic exposure, suggests a study.

In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).

Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.